Article | October 11, 2016

Reducing Upstream Processing Scale-Up Risks Using QbD

Reducing Upstream Processing Scale-Up Risks Using QbD

By Mario Becker, Tim Ward and Christel Fenge

Scientists and engineers seeking to develop manufacturing processes for new biopharmaceutical drugs face a number of challenges. Upstream process development must deliver a high-yielding cell culture to meet Cost of Goods (CoGs) objectives. The process must be robust to ensure high batch success rates with a low risk of contaminations and minimal variations in cell growth performance. The biological product must maintain the required product quality attributes, during scale-up from laboratory to commercial scale. Biopharmaceutical companies must address these complex challenges in the shortest possible timeframe and at reasonable effort and cost during development. Doing so allows the early evaluation of products in the clinic and, therefore, effective resource allocation behind projects from the pipeline that are most likely to be successful all the way to the market.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: